title: Molecular imaging by cardiovascular MR.
abstract: Do molecularly-targeted contrast agents have what it takes to usher in a paradigm shift as to how we will image cardiovascular disease in the near future? Moreover, are non-invasive vulnerable plaque detection and preemptive treatments with these novel nanoparticulate agents within reach for clinical applications? In this article, we attempt to make a compelling case for how the advent of molecularly-targeted nanoparticle technology may change the way we detect atherosclerotic lesions, determine their clinical significance and even provide non-invasive treatments. Focusing on imaging with cardiovascular MR, an overview of the latest developments in this rapidly evolving field of so-called "intelligent" contrast agents that are able to interrogate the vascular wall and various complementary advanced imaging technologies are presented.
authors: Division of Cardiology, Washington University School of Medicine, St. Louis, MO 63108, USA.
authors: Tillmann
authors: T
authors: Cyrus
authors: Gregory M
authors: GM
authors: Lanza
authors: Samuel A
authors: SA
authors: Wickline
mesh_terms: D000818:Animals; D017209:Apoptosis; D050197:Atherosclerosis / Q000175:diagnosis* / Q000517:prevention & control; D003287:Contrast Media / Q000494:pharmacology*; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D053758:Nanoparticles; D009389:Neovascularization, Pathologic / Q000175:diagnosis / Q000517:prevention & control
chemical_list: D003287:Contrast Media